These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 15262305)

  • 1. Current management strategies for cutaneous T-cell lymphoma.
    Knobler E
    Clin Dermatol; 2004; 22(3):197-208. PubMed ID: 15262305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG
    J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of cutaneous T-cell lymphomas].
    Rappersberger K; Ortel B; Forstinger C; Wolff K
    Wien Klin Wochenschr; 1994; 106(10):300-8. PubMed ID: 8053197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and experimental skin-directed therapies for cutaneous lymphomas.
    Farkas A; Kemeny L; French LE; Dummer R
    Skin Pharmacol Physiol; 2009; 22(6):322-34. PubMed ID: 19786826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of phototherapy in cutaneous T-cell lymphoma.
    Pothiawala SZ; Baldwin BT; Cherpelis BS; Lien MH; Fenske NA
    J Drugs Dermatol; 2010 Jul; 9(7):764-72. PubMed ID: 20677530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cutaneous T-cell lymphoma: an update.
    Young JW
    J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cutaneous T-cell lymphoma.
    Zackheim HS
    Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on treatment of cutaneous T-cell lymphoma.
    Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
    Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
    Dummer R; Assaf C; Bagot M; Gniadecki R; Hauschild A; Knobler R; Ranki A; Stadler R; Whittaker S
    Eur J Cancer; 2007 Nov; 43(16):2321-9. PubMed ID: 17707638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic approaches in cutaneous lymphoma.
    Jörg B; Kerl H; Thiers BH; Bröcker EB; Burg G
    Dermatol Clin; 1994 Apr; 12(2):433-41. PubMed ID: 8045054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
    Dummer R; Foss F; Dreno B; Bagot M
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous T cell lymphoma: update on treatment.
    Wollina U
    Int J Dermatol; 2012 Sep; 51(9):1019-36. PubMed ID: 22909354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone marrow autograft in the treatment of cutaneous lymphoma].
    Zeitoun C; Baccard M; Marolleau JP; Rybojad M; Baruchel A; Morel P; Brice P
    Ann Dermatol Venereol; 1996; 123(2):79-84. PubMed ID: 8761756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy options in cutaneous T-cell lymphoma.
    Apisarnthanarax N; Duvic M
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):403-20. PubMed ID: 12113107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.